Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme (PBS) Data

IF 2.1 4区医学 Q2 NURSING

Australian Journal of Rural Health Pub Date : 2025-09-23 DOI:10.1111/ajr.70094

Patricia A. Logan, Peter S. Micalos, Shanna Fealy, Marguerite Bramble, Alfred Wong

{"title":"Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme (PBS) Data","authors":"Patricia A. Logan, Peter S. Micalos, Shanna Fealy, Marguerite Bramble, Alfred Wong","doi":"10.1111/ajr.70094","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Explore Parkinson's Disease (PD) related prescription patterns for people with PD living in metropolitan and non-metropolitan areas of New South Wales, Australia.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Exploratory, cross-sectional data linkage study. Participants were grouped according to geographic location and by age group: metropolitan or non-metropolitan; rural, regional, and remote. Prescription patterns were analysed using descriptive and inferential statistics.</p>\n </section>\n \n <section>\n \n <h3> Design</h3>\n \n <p>The Sax Institute's 45 and Up Study data was linked to the Pharmaceutical Benefits Scheme (PBS) records (2004–2017) for all participants with PD.</p>\n </section>\n \n <section>\n \n <h3> Setting</h3>\n \n <p>Retrospective data exploration and analysis.</p>\n </section>\n \n <section>\n \n <h3> Participants</h3>\n \n <p>1648 participants who self-identified as having PD and voluntarily contributed to the 45 and Up longitudinal study.</p>\n </section>\n \n <section>\n \n <h3> Main Outcome Measures</h3>\n \n <p>Statistical comparisons based on location were undertaken for the different groupings for PD-specific medications.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Significant differences in the proportions of PD-related medications are observed between locations. Significant differences in the proportions of PD-related medications are observed between locations. A higher proportion of levodopa and levodopa combinations is reported for major cities (75.5%) compared with the inner region (70.3%) and outer and remote regions (74.1%). Additionally, other PD-related medications in the non-metropolitan areas are proportionally higher than those reported for major cities. Analysis by age groups suggests large effect sizes for the 75–79 and 45–49 age groups, while medium and small effect sizes are reported for the 55–59 and 70–74 age groups, respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Inequities with best practice medication treatment for PD exist between metropolitan and non-metropolitan areas of NSW. Efforts are required to successfully bridge gaps. Upskilling GPs may provide one way to optimise therapy and quality of life.</p>\n </section>\n </div>","PeriodicalId":55421,"journal":{"name":"Australian Journal of Rural Health","volume":"33 5","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12456107/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian Journal of Rural Health","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajr.70094","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NURSING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Explore Parkinson's Disease (PD) related prescription patterns for people with PD living in metropolitan and non-metropolitan areas of New South Wales, Australia.

Methods

Exploratory, cross-sectional data linkage study. Participants were grouped according to geographic location and by age group: metropolitan or non-metropolitan; rural, regional, and remote. Prescription patterns were analysed using descriptive and inferential statistics.

Design

The Sax Institute's 45 and Up Study data was linked to the Pharmaceutical Benefits Scheme (PBS) records (2004–2017) for all participants with PD.

Setting

Retrospective data exploration and analysis.

Participants

1648 participants who self-identified as having PD and voluntarily contributed to the 45 and Up longitudinal study.

Main Outcome Measures

Statistical comparisons based on location were undertaken for the different groupings for PD-specific medications.

Results

Significant differences in the proportions of PD-related medications are observed between locations. Significant differences in the proportions of PD-related medications are observed between locations. A higher proportion of levodopa and levodopa combinations is reported for major cities (75.5%) compared with the inner region (70.3%) and outer and remote regions (74.1%). Additionally, other PD-related medications in the non-metropolitan areas are proportionally higher than those reported for major cities. Analysis by age groups suggests large effect sizes for the 75–79 and 45–49 age groups, while medium and small effect sizes are reported for the 55–59 and 70–74 age groups, respectively.

Conclusion

Inequities with best practice medication treatment for PD exist between metropolitan and non-metropolitan areas of NSW. Efforts are required to successfully bridge gaps. Upskilling GPs may provide one way to optimise therapy and quality of life.

Abstract Image

查看原文本刊更多论文

比较澳大利亚新南威尔士州按地点分类的帕金森病药物：将45及以上研究与药物福利计划（PBS）数据联系起来。

目的：探讨澳大利亚新南威尔士州大都市和非大都市地区帕金森病患者的相关处方模式。方法：探索性、横断面数据关联研究。参与者根据地理位置和年龄分组：大都市或非大都市；农村、地区和偏远。使用描述性和推理统计分析处方模式。设计：Sax研究所的45和Up研究数据与所有PD参与者的药物福利计划（PBS）记录（2004-2017）相关联。设置：回顾性数据探索和分析。参与者：1648名自认为患有PD并自愿参与45岁及以上纵向研究的参与者。主要结果测量：对pd特异性药物的不同分组进行了基于地点的统计比较。结果：不同地区pd相关药物的使用比例有显著差异。不同地区pd相关药物的比例有显著差异。主要城市左旋多巴和左旋多巴联合使用的比例（75.5%）高于内陆地区（70.3%）和偏远地区（74.1%）。此外，其他pd相关药物在非大都市地区的比例高于主要城市。按年龄组分析表明，75-79岁和45-49岁年龄组的效应量较大，而55-59岁和70-74岁年龄组的效应量分别为中等和较小。结论：新南威尔士州大都市与非大都市之间存在PD最佳实践药物治疗的不平等。需要努力成功地弥合差距。提高全科医生的技能可能会提供一种优化治疗和生活质量的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australian Journal of Rural Health 医学-公共卫生、环境卫生与职业卫生

CiteScore

2.30

自引率

16.70%

发文量

122

审稿时长

12 months

期刊介绍： The Australian Journal of Rural Health publishes articles in the field of rural health. It facilitates the formation of interdisciplinary networks, so that rural health professionals can form a cohesive group and work together for the advancement of rural practice, in all health disciplines. The Journal aims to establish a national and international reputation for the quality of its scholarly discourse and its value to rural health professionals. All articles, unless otherwise identified, are peer reviewed by at least two researchers expert in the field of the submitted paper.